Description of the first genetically confirming case with Donahue’s syndrome in Russia
https://doi.org/10.14341/probl201662242-45
Abstract
Syndrome Donahue (leprechaunism) is a rare form of neonatal diabetes mellitus associated with INSR gene mutations.
There are three types of insulin resistance syndrome: Donohue syndrome, Rabson—Mendenhall syndrome and insulin resistance type A. These syndromes are distinguished from one another by severity of symptoms, age of onset and age of death. Donohue and Rabson—Mendenhall syndromes are associated with biallelic mutations in the α-subunit or/and β-subunit of INSR gene and are characterized by more severe phenotype and poor prognosis. Patients with Donohue syndrome usually die within the first two years of life. Life expectancy of patients with Rabson—Mendenhall syndrome is 5—15 years.
Most patients with insulin resistance type A have heterozygous mutations in the β-subunit and demonstrate mild phenotype.
Here, we describe the first genetically confirmed case of syndrome Donahue in the Russian Federation.
Keywords
перманентный неонатальный сахарный диабет,
синдром Донахью,
лепрехаунизм,
мутации в INSR,
инсулинорезистентность
Supporting agencies: permanent neonatal diabetes mellitus; donohue syndrome; leprechaunism; insr gene mutations; insulin resistance
About the Authors
Yulia V. Tikhonovich
Endocrinology Research Centre
Russian Federation
MD, PhD, Assistant researcher
Competing Interests: конфликт интересов отсутствует
Russian Federation
MD, PhD, Assistant researcher
Competing Interests: конфликт интересов отсутствует
Oleg A. Malievsky
Republican Children Clinical Hospital
Russian Federation
MD, PhD, Professor
Competing Interests: конфликт интересов отсутствует
Russian Federation
MD, PhD, Professor
Competing Interests: конфликт интересов отсутствует
Anatoly Tyul'pakov
Endocrinology Research Centre
Russian Federation
MD, PhD, Head of the Generic endocrinopathies department, Clinical Endocrinology Institute
Competing Interests: конфликт интересов отсутствует
Russian Federation
MD, PhD, Head of the Generic endocrinopathies department, Clinical Endocrinology Institute
Competing Interests: конфликт интересов отсутствует
References
1. Donohue WL. Clinicopathologic Conference at the Hospital for Sick Children. J Pediatr. 1948;32(6):739-748. doi: 10.1016/s0022-3476(48)80231-3.
2. Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr. 1954;45(5):505-519. doi: 10.1016/s0022-3476(54)80113-2.
3. Taylor SI, Kadowaki T, Kadowaki H, et al. Mutations in Insulin-Receptor Gene in Insulin-Resistant Patients. Diabetes Care. 1990;13(3):257-279. doi: 10.2337/diacare.13.3.257.
4. Longo N, Wang Y, Smith SA, et al. Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet. 2002;11(12):1465-1475. doi: 10.1093/hmg/11.12.1465.
5. Musso C, Cochran E, Moran SA, et al. Clinical Course of Genetic Diseases of the Insulin Receptor (Type A and Rabson—Mendenhall Syndromes). Medicine. 2004;83(4):209-222. doi: 10.1097/01.md.0000133625.73570.54.
6. Schilling EE, Rechler MM, Grunfeld C, Rosenberg AM. Primary defect of insulin receptors in skin fibroblasts cultured from an infant with leprechaunism and insulin resistance. Proc Natl Acad Sci U S A. 1979;76(11):5877-5881. PMC411755.
7. Psiachou H, Mitton S, Alaghband-Zadeh J, et al. Leprechaunism and homozygous nonsense mutation In the insulin receptor gene. The Lancet. 1993;342(8876):924. doi: 10.1016/0140-6736(93)91970-w.
8. Ebina Y, Ellis L, Jarnagin K, et al. The human insulin receptor cDNA: The structural basis for hormone-activated transmembrane signalling. Cell. 1985;40(4):747-758. doi: 10.1016/0092-8674(85)90334-4.
9. Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 1985;313(6005):756-761. doi: 10.1038/313756a0.
10. White MF, Kahn CR. The insulin signaling system. J Biol Chem. 1994;269(1):1-4.
11. Seino S, Seino M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. Proc Nat Acad Sci. 1989;86(1):114-118.
12. Thiel CT, Knebel B, Knerr I, et al. Two novel mutations in the insulin binding subunit of the insulin receptor gene without insulin binding impairment in a patient with Rabson—Mendenhall syndrome. Mol Genet Metab. 2008;94(3):356-362. doi: 10.1016/j.ymgme.2008.02.013.
13. Taylor SI, Kadowaki T, Kadowaki H, et al. Mutations in Insulin-Receptor Gene in Insulin-Resistant Patients. Diabetes Care. 1990;13(3):257-279. doi: 10.2337/diacare.13.3.257.
14. Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes. 1992;41(11):1473-1490. doi: 10.2337/diabetes.41.11.1473.
15. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: 2008 update. Genome Med. 2009;1(1):13. doi: 10.1186/gm13.
16. Thiel CT, Knebel B, Knerr I, et al. Two novel mutations in the insulin binding subunit of the insulin receptor gene without insulin binding impairment in a patient with Rabson–Mendenhall syndrome. Mol Genet Metab. 2008;94(3):356-362. doi: 10.1016/j.ymgme.2008.02.013.
17. Hovnik T, Bratanič N, Podkrajšek KT, et al. Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation. Eur J Pediatr. 2012;172(8):1125-1129. doi: 10.1007/s00431-012-1901-7.
18. Falik Zaccai TC, Kalfon L, Klar A, et al. Two novel mutations identified in familial cases with Donohue syndrome. Molecular Genetics & Genomic Medicine. 2014;2(1):64-72. doi: 10.1002/mgg3.43.
19. Baykan A, Cansever M, Konuskan B, et al. Hypertrophic Cardiomyopathy with Leprechaunism. J Pediatr Endocrinol Metab. 2008;21(4). doi: 10.1515/jpem.2008.21.4.317.
20. Simpkin A, Cochran E, Cameron F, et al. Insulin Receptor and the Kidney: Nephrocalcinosis in Patients with Recessive INSR Mutations. Nephron Physiology. 2014;128(3-4):55-61. doi: 10.1159/000366225.
21. Agarwal AK, Simha V, Oral EA, et al. Phenotypic and Genetic Heterogeneity in Congenital Generalized Lipodystrophy. J Clin Endocr Metab. 2003;88(10):4840-4847. doi: 10.1210/jc.2003-030855.
22. Brown RJ, Cochran E, Gorden P. Metreleptin Improves Blood Glucose in Patients With Insulin Receptor Mutations. J Clin Endocr Metab. 2013;98(11):E1749-E1756. doi: 10.1210/jc.2013-2317.
23. Weber DR, Stanescu DE, Semple R, et al. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. J Pediatr Endocrinol Metab. 2014;0(0). doi: 10.1515/jpem-2013-0402.
24. Schoenle EJ, Zenobi PD, Torresani T, et al. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia. 1991;34(9):675-679. doi: 10.1007/bf00400998.
25. Kitamei H, Yokoi M, Kase M, Ohno S. Retinal neovascularization during treatment with IGF-1 for insulin resistance syndrome. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2005;243(7):715-717. doi: 10.1007/s00417-004-1093-6.
26. Jo W, Sudo S, Nakamura A, et al. Development of Endometrial Carcinoma in a Patient with Leprechaunism (Donohue Syndrome). Clinical Pediatric Endocrinology. 2013;22(2):33-38. doi: 10.1297/cpe.22.33. doi: 10.14341/probl201662242-45
Supplementary files
Review
For citations:
Tikhonovich Yu.V., Malievsky O.A., Tyul'pakov A. Description of the first genetically confirming case with Donahue’s syndrome in Russia. Problems of Endocrinology. 2016;62(2):42-45. https://doi.org/10.14341/probl201662242-45
Views:
3623
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
